Robert H. Dworkin
Chair of Scientific Advisory BoardDr. Robert H. Dworkin, Ph.D., is Chair of Scientific Advisory Board at Pelthos Therapeutics Inc. (formerly known as Channel Therapeutics Corporation) (formerly known as Chromocell Therapeutics Corporation). He serves as Member of Scientific Advisory Board at Oxford Cannabinoid Technologies Holdings plc since April 2022 and serves as its Consultant since November 2021. He served as a Member of GTX-101 Scientific Advisory Board at Acasti Pharma Inc. since August 2021 until 2022. He serves as a Director at Ethismos Research, Inc. Dr. Dworkin serves as a Member of Scientific Advisory at Shanghai SIMR Biotechnology Co.,Ltd. He has been Member of Scientific Advisory Board at Definium Therapeutics, Inc. (formerly known as Mind Medicine (MindMed) Inc.) since August 2021. He serves as Member of Advisory Board at Confo Therapeutics since July 2021. He served as Member of Strategic Advisory Board at NeuroBo Pharmaceuticals, Inc. until March 2023. He serves as a Scientific Advisor at Collegium Pharmaceutical, Inc. and Spinifex Pharmaceuticals Pty Limited. Dr. Dworkin is Professor of Anesthesiology, Perioperative Medicine, Neurology, Oncology and Psychiatry at the University Of Rochester Medical Center. He serves as Director of the Anesthesiology Clinical Research Center at the University of Rochester School of Medicine and Dentistry and Director of Psychological Services, Strong Pain Clinic. He serves as Member of Scientific Advisory Board at Regenacy Pharmaceuticals, Inc. He serves as a Member of Medical and Scientific Advisory Board at Neurogesx, Inc. and Charleston Laboratories, Inc. He is the Associate Editor of the Clinical Journal of Pain, Chairman of the International Conference on the Mechanisms and Treatment of Neuropathic Pain, Vice Chairmaan of the Special Interest Group on Neuropathic Pain, International Association for the Study of Pain, Co-Chairman of Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT) and Consultant to numero- private and government agencies and Partnerships. He has served as a Consultant to over 100 pharmaceutical and device companies in the development and evaluation of analgesic and antiviral treatments. He serves as Director of the Analgesic, Anesthetic and Addiction Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION). His research focuses primarily on examining the relationships between study methodologic features and study outcomes in acute and chronic pain trials, as well as comparing the responsiveness to treatment effects of different primary and secondary outcome measures. He is a Member of the US Centers for Disease Control and Prevention (CDC) Zoster Working Group and a Special Government Employee of the FDA Center for Drug Evaluation and Research. He is a Principal Investigator for numerous clinical trials of analgesic treatments. He served as a Member of Pain Medical Advisory Board at Hydra Biosciences, Inc. since June 4, 2015. He is an Associate Editor of Pain and serves on the editorial boards of Journal of Pain and Current Pain and Headache Reports. He received the American Pain Society's Wilbert E Fordyce Clinical Investigator Award in 2005, the Eastern Pain Association's John J Bonica Award in 2011 and the American Pain Society's John and Emma Bonica Public Service Award in 2014. Dr. Dworkin received a B.A. in Psychology from the University of Pennsylvania in 1971 and a Ph.D. in Psychology from Harvard University in 1977.
Positions
- Company NamePelthos Therapeutics Inc.Stock CodePTHSPositionChair of Scientific Advisory Board
